Impact of Vaccination in Acute COVID-19

N/ACompletedNCT05198453

University Medical Centre Ljubljana529 enrolled

Overview

The aim of this study was to evaluate the association between vaccination with one of the four SARS-CoV-2 vaccines authorized for use in the European Union-BNT162b2, ChAdOx-1S, mRNA-1273 or Ad.26.COV2.S-and progression to critically severe disease among adult patients with PCR-confirmed acute COVID-19.

Study Type

OBSERVATIONAL

Enrollment

529

Conditions

COVID-19

Interventions

vaccinationBIOLOGICAL

patients who received COVID-19 vaccine

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age 18 yers or more * hospitalized for acute COVID-19 * PCR confirmed infection with SARS-CoV-2 Exclusion Criteria: * hospitalized for other conditions

Locations (1)

University Medical Center Ljubljana

Ljubljana, Slovenia

Outcomes

Primary Outcomes

number (%) with critically severe disease

Time frame: assessment performed at a minimum 30 days after admission

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.